Osmotica Pharmaceuticals (NASDAQ:OSMT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

A number of other equities research analysts have also recently issued reports on OSMT. Wells Fargo & Co set a $14.00 target price on shares of Osmotica Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, March 28th. Barclays initiated coverage on shares of Osmotica Pharmaceuticals in a research report on Tuesday, June 11th. They issued an “overweight” rating and a $11.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $14.00.

Shares of Osmotica Pharmaceuticals stock opened at $3.29 on Friday. The stock has a market capitalization of $171.57 million and a PE ratio of -6.45. Osmotica Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $9.90. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.70 and a quick ratio of 1.41.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.08). The firm had revenue of $57.13 million for the quarter, compared to the consensus estimate of $53.58 million. As a group, analysts anticipate that Osmotica Pharmaceuticals will post -0.25 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of OSMT. SG Americas Securities LLC bought a new stake in Osmotica Pharmaceuticals during the first quarter worth about $45,000. American International Group Inc. bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $50,000. Deutsche Bank AG bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $111,000. Northern Trust Corp bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $615,000. Finally, Geode Capital Management LLC bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $668,000. 11.64% of the stock is owned by institutional investors and hedge funds.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Recommended Story: Institutional Investors

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.